Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/or sorafenib in the phase III DECISION study

被引：0
|
作者：
Fassnacht, M. [1 ]
Kappeler, C. [2 ]
Healy, D. P. [3 ]
Baumer, C. [4 ]
Meinhardt, G. [3 ]
Elisei, R. [5 ]
Schlumberger, M. [6 ,7 ]
Brose, M. S. [8 ]
机构：
[1] Univ Klinikum Wurzburg, Wurzburg, Germany
[2] Bayer Pharma AG, Berlin, Germany
[3] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[4] BIOP AG, Basel, Switzerland
[5] Univ Pisa, Pisa, Italy
[6] Gustave Roussy, Villejuif, France
[7] Univ Paris 11, Villejuif, France
[8] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0277
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [41] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON AND SURVIVAL EXTRAPOLATION IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RAI-REFRACTORY DTC): UPDATED ANALYSIS
    Tremblay, G.
    Pelletier, C.
    Forsythe, A.
    Majethia, U.
    VALUE IN HEALTH, 2015, 18 (07) : A435 - A435
  • [42] Relationship between sarcopenia and dose-limiting toxicity (DLT) of sorafenib (SOR) in patients (pts) with advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) in the phase III DECISION trial.
    Huillard, Olivier
    Brose, Marcia S.
    Jouinot, Anne
    Tlemsani, Camille
    Arrondeau, Jennifer
    Meinhardt, Gerold
    Fellous, Marc Mardoche
    De Sanctis, Yoriko
    Schlumberger, Martin
    Goldwasser, Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC)
    Lorch, Jochen H.
    Busaidy, Naifa
    Ruan, Daniel T.
    Janne, Pasi A.
    Limaye, Sewanti Atul
    Wirth, Lori J.
    Barletta, Justine A.
    Rabinowits, Guilherme
    Garraway, Levi A.
    Van Allen, Eliezer Mendel
    Wagle, Nikhil
    Hanna, Glenn J.
    Misiukiewicz, Krzysztof
    Suda, Margaret
    Haddad, Tyler C.
    Devine, Catherine E.
    Williams, Amy
    Warsi, Ghulam
    Posner, Marshall R.
    Haddad, Robert I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses
    Brose, M.
    Jarzab, B.
    Elisei, R.
    Giannetta, L.
    Bastholt, L.
    de la Fouchardiere, C.
    Pacini, F.
    Paschke, R.
    Nutting, C.
    Shong, Y. K.
    Sherman, S.
    Smit, J.
    Chung, J.
    Meinhardt, G.
    Schlumberger, M.
    Kappeler, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer
    Tahara, Makoto
    Kiyota, Naomi
    Hoff, Ana O.
    Badiu, Corin
    Owonikoko, Taofeek K.
    Dutcus, Corina E.
    Suzuki, Takuya
    Ren, Min
    Wirth, Lori J.
    EUROPEAN JOURNAL OF CANCER, 2021, 147 : 51 - 57
  • [46] Clinical benefit and quality of life during low-dose sorafenib maintenance therapy in radioiodine refractory differentiated thyroid cancer patients: A historical cohort study
    Fallahi, Babak
    Moharrami, Khatere
    Beiki, Davood
    Fard-Esfahani, Armaghan
    Alimoghaddam, Kamran
    Eftekhari, Mohammad
    IRANIAN JOURNAL OF NUCLEAR MEDICINE, 2023, 31 (01): : 42 - 48
  • [47] Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
    Seiichi Hayato
    Robert Shumaker
    Jim Ferry
    Terri Binder
    Corina E. Dutcus
    Ziad Hussein
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 971 - 978
  • [48] OUTCOMES BY SITE OF METASTASIS FOR PATIENTS WITH RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER TREATED WITH LENVATINIB VERSUS PLACEBO: RESULTS FROM A PHASE 3, RANDOMIZED TRIAL
    Young, Louise
    Habra, Mouhammed
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 134 - 134
  • [49] Does the Use of Amifostine for Salivary Gland Protection Reduce the Rate of Thyroid Remnant Ablation in Patients with Differentiated Thyroid Cancer Receiving Radioiodine Therapy?
    Haindl, W.
    Ting, A. C. C.
    Rossleigh, M. A.
    Som, S. S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S122 - S122
  • [50] Impact of lung metastasis on overall survival (OS) in the phase III SELECT study with lenvatinib (LEN) in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)
    Tahara, M.
    Kiyota, N.
    Hoff, A. O.
    Badiu, C.
    Owonikoko, T. K.
    Dutcus, C. E.
    Suzuki, T.
    Ren, M.
    Misir, S.
    Wirth, L. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 756 - 756
12345